Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

Academy · Research Data, Analytics & AI · Translational Research Ecosystems

Translational Research Ecosystems: What Drives Academia-Industry Biomedical Innovation

Moving a biomedical discovery from the laboratory to a usable therapy depends less on the science alone than on whether academia, funders and industry can bridge the so-called valley of death between early discovery and investable development.

Pubrica AcademyWritten by a translational research consultant Reviewed bya biomedical research strategist Published10 October 2026 Last checked10 October 2026 Reading time12 minutes Sources17 sources

A translational research ecosystem is the network of academic researchers, funding bodies, regulators, industry partners and clinicians whose coordination determines whether a biomedical discovery actually reaches patients. Mahant, writing in the Journal of Translational Medicine, frames translational medicine itself as an ecosystem of interrelated but not always aligned stakeholders — patients, researchers, commercialisation teams, investors, regulators, ethics bodies and payers — whose differing incentives shape how fast, and whether, a discovery moves forward.

Entrepreneurial and translational ecosystems at a glance

The subject
Entrepreneurial ecosystems: the actors and conditions that turn ideas into new firms and products
Components
Academics, business, government and community, plus human capital, networks, culture, finance, governance, infrastructure, environmental resources and markets11
Emerging-economy example
In Iran’s health sector, weak infrastructure and support systems were ranked the most important barrier14
Biomedical case
153 FDA-approved drugs, vaccines or new indications were discovered in public-sector research over 40 years16
This article’s focus
The academia–industry ecosystem that moves biomedical discoveries towards patients
Reading time
About 12 minutes, with 3 figures and 2 tables

What you will learn

  • Most drug discovery still originates in academic institutions, with industry taking on the capital-intensive work of validation and commercialisation.
  • The 'valley of death' describes the funding gap between a promising early discovery and the capital needed to validate it for commercial development.
  • Academic centres such as the University of Pennsylvania's ITMAT and Stanford's SPARK programme were created specifically to bridge that gap.
  • Academia-industry partnerships are associated with an increase in high-impact co-publications, a signal that collaboration strengthens rather than dilutes research output.

What to unlearn

  • “Academia and industry want the same thing from a biomedical partnership, so collaboration is mainly a logistics problem.” Mahant's account of the ecosystem describes structurally different incentives: academia weighs scientific credibility and publication, while industry must weigh capital risk, market size, and regulatory and reimbursement pathways before committing resources, and friction over intellectual property ownership and compensation is a recognised source of strain between the two.
  • “The main obstacle to translating a discovery is scientific, not organisational.” The valley-of-death problem described in the ecosystem literature is fundamentally a funding and coordination failure between the point where a finding is scientifically promising and the point where it is investable, not a gap in the underlying science itself.

Entrepreneurial Ecosystems in Advanced and Emerging Economies

An entrepreneurial ecosystem is the set of interdependent actors and conditions in a place that enables new ventures to form and grow. A bibliometric mapping by Asmit and colleagues in Heliyon groups the components into actors (academics, business, government and community) and non-actor conditions (human capital, networks, entrepreneurial culture, financial systems, governance systems, infrastructure, environmental resources and markets), and argues that environmental resources distinguish rural ecosystems from the urban ones most studies describe11. Figure 1 sets out the four actor groups.

AAcademicsUniversities and research institutes that generate knowledge, people and intellectual property
BBusinessEstablished firms, start-ups and investors that develop and finance products
GGovernmentFunders, regulators and policy-makers that set the rules and fill market gaps
CCommunityNetworks, culture and local users that shape demand and legitimacy
Figure 1. The four actor components of an entrepreneurial ecosystem identified by Asmit et al., who add eight non-actor conditions: human capital, networks, entrepreneurial culture, financial systems, governance systems, infrastructure, environmental resources and markets. The descriptions under each heading are Pubrica’s summaries.11

The concept has been criticised for assuming that every entrepreneur has equal access to these resources. A systematic review of 111 publications by Lois and colleagues in Small Business Economics found that most work either treats entrepreneurs as a homogeneous group or examines a single category of difference, most often gender, and proposes an intersectional framework in its place12. The comparison between advanced and emerging economies is one way of making those differences visible. Using Global Entrepreneurship Monitor survey data, Wei and colleagues found that entrepreneurial resources were associated with more start-up activity, and that entrepreneurial orientation mediated the relationship in countries where resources were scarce as well as where they were plentiful13. Table 1 sets four PubMed-indexed studies side by side.

Table 1. Entrepreneurial ecosystems in advanced and emerging economies: four PubMed-indexed studies

StudySettingDesignWhat it reports
Schaft and Füller 2023, EMBO Reports15Advanced: Rhine-Main-Neckar life-science region around Heidelberg, GermanyPractitioner accountAttributes the region’s growth to high density, critical mass and effective strategies
Njoku et al. 2023, Digital Health17Advanced: accelerator programmes for digital health in the UK National Health ServiceInterviews with representatives of 9 SMEs across 3 programmesAccelerators helped adoption, but demands for traditional research evidence and system-level barriers persisted
Jamali et al. 2025, J Educ Health Promot14Emerging: the Iranian health systemFocus groups with 16 entrepreneurs, policy-makers, executives and researchers60 challenges; ranked in importance: infrastructure and support, sociocultural factors, human capital, market, financing, health policy
Wei et al. 2023, Heliyon13Cross-national, including emerging economiesGlobal Entrepreneurship Monitor Adult Population Survey dataEntrepreneurial orientation mediates the link between resources and start-up activity

Most entrepreneurial-ecosystem research appears in economics and management journals that PubMed does not index. This table is limited to studies retrievable through PubMed and is an introduction, not a systematic comparison.

Why this article concentrates on biomedical translation

The peer-reviewed evidence on how an ecosystem converts research into marketable products is densest for drug and device development, where academic discovery, industry capital and regulatory approval can each be traced, so the remainder of this article examines the academia–industry ecosystem in biomedicine as a worked case of the general concept.

What Counts as a Translational Research Ecosystem

Mahant describes the translational medicine ecosystem as a network of stakeholders that includes patients, researchers, commercialisation teams, investors, regulators, ethics bodies and payers, each with a distinct and sometimes conflicting stake in how a discovery is developed1. Historically, drug discovery has started within academic institutions, with named examples including Copaxone, Emtriva and Taxol as drugs that originated in academic research before industry partners carried them through development1.

The academic share of discovery has been quantified. Stevens and colleagues, in the New England Journal of Medicine, identified 153 FDA-approved drugs, vaccines or new indications for existing drugs that had been discovered in public-sector research institutions over the preceding 40 years; more than half were used to treat or prevent cancer or infectious diseases (Figure 2)16.

153 FDA-approved products discovered in public-sector research, by type

Small-molecule drugs93 of 15360.8%
Biologic agents36 of 15323.5%
Vaccines15 of 1539.8%
In vivo diagnostic materials8 of 1535.2%
Over-the-counter drug1 of 1530.7%

Percentages calculated by Pubrica from the counts reported by Stevens et al.; bars are drawn on a 0–100% scale.

Figure 2. Products discovered in public-sector research institutions and approved by the FDA over 40 years, by type. Source: Stevens et al., New England Journal of Medicine, 2011.16

Table 2. General ecosystem components and their counterparts in biomedical translation

Ecosystem componentBiomedical counterpart discussed in this article
AcademicsUniversity laboratories and translational centres such as ITMAT and SPARK
BusinessPharmaceutical science hubs, biotech ventures and commercial trial sponsors
GovernmentPublic research funders, patent policy such as the Bayh-Dole Act, and regulatory pathways such as Breakthrough Therapy designation
Financial systemsVenture philanthropy, early-stage venture investors and pharmaceutical partnering across the valley of death
Infrastructure and networksShared early-phase trial capacity such as the UK’s Experimental Cancer Medicine Centre network
GovernanceConflict-of-interest rules and intellectual property agreements between partners

Pubrica’s mapping of the components identified by Asmit et al. onto the sections of this article; it is an organising device, not a finding.11

The Valley of Death and Funding Gaps

The central obstacle in the ecosystem is what Mahant calls the "valley of death" — the gap between a scientifically promising early-stage discovery and the capital required to validate it to a point where it becomes commercially investable1. Early-stage biotech ventures are particularly exposed to this gap, since they have neither the revenue of an established company nor the direct public funding available to a university laboratory. The University of Massachusetts Chan Medical School's own description of the problem is specific about where the gap sits: NIH funding generally covers mechanistic, discovery-stage research but stops short of drug development, while venture and pharmaceutical investors typically wait until late preclinical or early clinical risk has already been reduced before committing significant capital2.

1Discovery in an academic or public-sector laboratory, usually grant-fundedAcademia
2Validation to the point of investability: too applied for most grants, too early for most investorsValley of death
3Development, trials and manufacturing financed by industryIndustry
4Approval and uptake into practice and policy, the later T2–T4 stagesRegulators and health systems
Figure 3. Where the valley of death sits in the translational pathway. Conceptual summary of the sources discussed in this section; not drawn from any single study.

Institutional Bridges Between Academia and Industry

In response, pharmaceutical companies have set up dedicated "science hubs" in partnership with universities, while academic institutions have built translational centres of their own, including the University of Pennsylvania's Institute for Translational Medicine and Therapeutics (ITMAT) and Stanford's SPARK programme1. These bridging institutions exist specifically to manage the cultural and incentive differences between the two sides — differences in trust, intellectual property ownership and compensation structures that can otherwise strain a partnership1.

Measurable Outcomes of Academia-Industry Collaboration

Where the partnership works, each side contributes something the other lacks: academia offers scientific credibility, early-stage research expertise, intellectual property and comparatively lower personnel costs, while industry offers the capital, regulatory experience and commercialisation pathway needed to bring a product to market1. Mahant notes that academia-industry partnerships have been associated with an increase in high-impact co-publications, and that collaborations are increasingly international, citing the UK's Experimental Cancer Medicine Centre network as an example1.

The T1-T4 Spectrum and Why Translation Takes So Long

The ecosystem Mahant describes maps onto a widely used translational-research spectrum: T1 moves a discovery from the laboratory bench to an initial patient-facing treatment, T2 moves a proven treatment into broader clinical practice, and later T3 and T4 stages extend that further into community-level implementation and population-level policy impact3. Each additional stage adds its own coordination problem, which is part of why the overall pipeline is so slow: Westfall, Mold and Fagnan's widely cited estimate in JAMA is that it takes roughly 17 years for only about 14% of new scientific discoveries to reach routine clinical practice10, a figure the T1-T4 translational-research literature treats as the baseline the whole ecosystem is trying to improve on3. The valley of death that Mahant describes sits specifically at the T1 boundary, but the ecosystem's coordination failures do not end once a therapy reaches patients once — they recur at every later stage of the T1-T4 spectrum.

Who Actually Fills the Valley-of-Death Gap

Because neither NIH-style public funding nor late-stage private capital is designed to cover the gap in between, the institutions that have emerged to fill it tend to be hybrids. Venture philanthropy funds, angel-style early-stage venture investors, and non-exclusive early engagement with pharmaceutical partners are the three mechanisms most commonly used to bridge the gap before a discovery is derisked enough for conventional investment2. Some academic medical centres have gone further and built their own early manufacturing and proof-of-concept trial capability in-house specifically so a discovery does not have to wait for outside capital to generate the data that outside capital would otherwise demand first2.

Vague ecosystem statement

“We will seek industry partners to commercialise the findings.”

Names no partner type, no funding source for validation and no point at which the work becomes investable.

Specific ecosystem statement

“Lead optimisation will be funded through [translational programme]; proof-of-concept data from [milestone] will be shared under a non-exclusive evaluation agreement with two pharmaceutical partners before licensing is negotiated.”

States who funds the gap, what evidence closes it and how industry is engaged without foreclosing options.

Illustrative grant-application sentences written for this page; bracketed items are placeholders.

What SPARK and ITMAT-Style Centres Actually Do

Stanford's SPARK programme, founded by Chemical and Systems Biology professor Daria Mochly-Rosen, is a concrete example of how a bridging institution operates in practice: it gives academic researchers structured access to drug- and diagnostic-development expertise, core laboratory facilities and funding, runs a graduate curriculum on translational development, and funds "SPARK Scholars" for an average of about two years while they advance a specific project4. The model has been influential enough that other institutions have since replicated it under their own names, which is itself evidence that the underlying coordination problem — scientists with a promising discovery and no structured route to de-risking it — is general rather than specific to Stanford.

The Citation and Publication-Output Evidence for Collaboration

The claim that collaboration strengthens rather than dilutes academic output is not just Mahant's assertion; it has been tested directly in bibliometric studies. Hicks' analysis of roughly 2.1 million US papers from 1981 to 1994 found that university-industry co-authored papers were cited more often on average than single-university papers, and made up a disproportionately large share of the 1,000 most-cited papers in the dataset5. A separate analysis of Canadian papers from 1980 to 2005 reached the same conclusion — university-industry co-authored work had higher average scientific impact than papers from either sector alone — and a cross-country analysis covering seven countries found that biomedical papers co-published with industry specifically showed a substantial citation-impact advantage over purely academic biomedical papers5. The caveat researchers in this literature consistently add is that the size of the effect depends on discipline, on the partner organisation's own research capacity, and on how committed both sides are to the collaboration, so the citation advantage is real on average but not guaranteed in any individual partnership5.

A Contrarian View: Does Patent Policy Slow Translation Down?

Not every account of the ecosystem is this optimistic about how well academia and industry currently connect. Link, Scott and Danziger, writing in Issues in Science and Technology, argue that the Bayh-Dole Act of 1980 — which requires US universities to seek patents on commercially promising federally funded discoveries — has, counterintuitively, become part of the problem rather than the solution6. In their analysis of NIH-funded Small Business Innovation Research projects, firms that partnered with a university were less likely to commercialise the resulting technology, retain project staff, or grow employment than comparable firms with no university partner, which they attribute to universities pushing patenting "too far upstream" and granting exclusive licenses that lock up basic knowledge other researchers and firms could otherwise build on6. Their recommendation — requiring NIH extramural grant recipients to make results public rather than defaulting to exclusive licensing — is a direct challenge to the assumption that more patenting automatically speeds translation; it suggests the ecosystem's institutional incentives can just as easily slow a discovery down as move it forward.

Why the Ecosystem Also Needs Conflict-of-Interest Rules

Because academic researchers in these partnerships often hold equity, consulting fees or royalty interests tied to the same discovery they are evaluating, the ecosystem's working requires explicit conflict-of-interest management rather than an assumption of goodwill. One commentary on industry-academia relationships in molecular imaging research puts the trade-off plainly: collaboration is necessary because academic researchers generate the ideas and industry has the resources to test and commercialise them, but the same arrangement carries a real risk of bias, undisclosed influence, or outright misconduct, and the author notes that no single national standard yet governs how institutions should manage it7. The proposed remedy is consistent across the ecosystem literature: honest, complete disclosure of financial relationships to patients, journals and institutions, rather than leaving conflict-of-interest management to each investigator's individual judgment7.

Regulatory Shortcuts Have Their Own Trade-Offs

The ecosystem's incentives also run through the regulator, not just through funders and universities. The FDA's Breakthrough Therapy designation, created by Congress through the 2012 Food and Drug Administration Safety and Innovation Act, speeds development and review for drugs treating serious conditions that show early evidence of a substantial improvement over existing therapies — a direct institutional attempt to shorten the translational pipeline8. A critique of the pathway summarised by Young, drawing on an analysis by Darrow, Avorn and Kesselheim, points out the trade-off this creates: smaller trials supporting these approvals can leave real gaps in safety and effectiveness data, and because the designation is sometimes read as an informal endorsement, it can increase public and regulatory pressure to approve a drug even where the risk-benefit picture is still uncertain8. For the ecosystem overall, this is a reminder that faster is not automatically safer, and that shortening one stage of the pipeline can simply shift evidentiary risk to the post-market stage instead of eliminating it.

A Working Example: The UK's Experimental Cancer Medicine Centre Network

Mahant's reference to the UK's Experimental Cancer Medicine Centre (ECMC) network as a model of international, cross-sector collaboration can be checked against the network's own operating figures. The ECMC Network functions as a single entry point connecting industry trial sponsors with academic sites that can run early-phase cancer trials, offering protocol development, feasibility assessment and patient-recruitment support; across its most recent reporting period it had 318 trials open to recruitment, of which about 70% were commercially sponsored, and had recruited 3,648 patients, with joint funding from Cancer Research UK, the Little Princess Trust, the NIHR and the health departments of Scotland, Wales and Northern Ireland9. The scale of commercial sponsorship inside an academically hosted network is itself evidence for Mahant's broader point: a well-designed bridging structure does not just subsidise academic research, it actively routes industry trial activity through academic sites in large volume.

Take-home message

Take-home message

A biomedical discovery moves from lab to patient only when the ecosystem around it — funding, institutional bridges and aligned incentives — closes the valley of death between early discovery and investable development.

How to apply this to your work

How to apply this to your own work

  1. Map the stakeholders early. Identify which funders, regulators and potential industry partners will need to be involved before the discovery can be validated, rather than only after it is market-ready.
  2. Plan for the funding gap explicitly. Treat the transition from early discovery to commercial-grade validation as a distinct funding stage that needs its own strategy, not an assumed continuation of grant funding.
  3. Use or build a bridging structure. Where available, route early translational work through an institutional technology-transfer office or translational centre designed to manage IP and industry relationships.

Common questions

It is the funding and resource gap between a discovery that is scientifically promising and the point at which it has been validated enough to attract commercial investment, a gap that is especially difficult for early-stage biotech ventures to cross on their own.

Mahant's account points to misaligned incentives and cultural friction — differing views on intellectual property ownership, compensation, and risk tolerance — as recurring sources of strain, separate from the quality of the underlying research.

Not necessarily. Link, Scott and Danziger's analysis of NIH-funded SBIR projects found that firms partnering with a university were actually less likely to commercialize the resulting technology than comparable firms without one, which they attribute to universities granting exclusive licenses that can lock up knowledge other researchers and firms could otherwise use.

No. Expedited pathways like the FDA's Breakthrough Therapy designation move a drug toward approval faster based on early evidence, but critics note this typically means smaller trials and more safety and effectiveness questions that are only resolved after the drug is already on the market.

References and sources

  1. Mahant V. Translational medicines "ecosystem". Journal of Translational Medicine. 2020;18:158. read 10 October 2026. View on PubMed Central
  2. UMass Chan Medical School, Office of Academic Innovation and Transformative Technologies. The valley of death: the funding gap between preclinical discoveries and early clinical trials. read 10 October 2026. View source
  3. Vukotich CJ Jr. Challenges of T3 and T4 translational research. Journal of Research Practice. 2016;12(2):Article P2. read 10 October 2026. View source
  4. Stanford SPARK Program. What is SPARK. read 10 October 2026. View source
  5. Murley S. Do partnerships with external organizations help or harm your research? McGill Reporter. 2016. read 10 October 2026. View source
  6. Link AN, Scott JT, Danziger RS. Is the Bayh-Dole Act stifling biomedical innovation? Issues in Science and Technology. 2018;34(2). read 10 October 2026. View source
  7. Industry-academia relationship: the need to collaborate and disclose. Health Imaging. read 10 October 2026. View source
  8. Young M. Expedited FDA approval for breakthrough therapies: promises and pitfalls. Petrie-Flom Center Bill of Health. 2014. read 10 October 2026. View source
  9. Experimental Cancer Medicine Centre (ECMC) Network. Working with Industry. read 10 October 2026. View source
  10. Westfall JM, Mold J, Fagnan L. Practice-based research: "Blue Highways" on the NIH roadmap. JAMA. 2007;297(4):403-406. read 10 October 2026. View source
  11. Asmit B, Simatupang TM, Rudito B, Novani S. Uncovering the building blocks of rural entrepreneurship: a comprehensive framework for mapping the components of rural entrepreneurial ecosystems. Heliyon. 2024;10(1):e24139. doi:10.1016/j.heliyon.2024.e24139 read 13 November 2026. doi.org/10.1016/j.heliyon.2024.e24139
  12. Lois M, Stingl I, Mayer H, Schäfer S. Exploring social difference among entrepreneurs in entrepreneurial ecosystems: a systematic review and intersectional framework. Small Business Economics. 2026;67(2):1073-1092. doi:10.1007/s11187-026-01216-5 read 13 November 2026. doi.org/10.1007/s11187-026-01216-5
  13. Wei Z, Lee MJ, Jia Z, Roh T. Do entrepreneurial resources drive startup activation? Mediating effect of entrepreneurial orientation. Heliyon. 2023;9(4):e15603. doi:10.1016/j.heliyon.2023.e15603 read 13 November 2026. doi.org/10.1016/j.heliyon.2023.e15603
  14. Jamali N, Emami SMH, Vatankhah S, Maleki MR. What are the challenges and barriers for the entrepreneurship ecosystem in the Iranian health system? A qualitative research. Journal of Education and Health Promotion. 2025;14:201. doi:10.4103/jehp.jehp_255_24 read 13 November 2026. doi.org/10.4103/jehp.jehp_255_24
  15. Schaft J, Füller S. Supporting a vibrant entrepreneurial ecosystem: high density, critical mass, and effective strategies underpin the success of innovative life science ecosystems. EMBO Reports. 2023;24(9):e57798. doi:10.15252/embr.202357798 read 13 November 2026. doi.org/10.15252/embr.202357798
  16. Stevens AJ, Jensen JJ, Wyller K, Kilgore PC, Chatterjee S, Rohrbaugh ML. The role of public-sector research in the discovery of drugs and vaccines. New England Journal of Medicine. 2011;364(6):535-541. doi:10.1056/NEJMsa1008268 read 13 November 2026. doi.org/10.1056/NEJMsa1008268
  17. Njoku C, Green Hofer S, Sathyamoorthy G, Patel N, Potts HWW. The role of accelerator programmes in supporting the adoption of digital health technologies: a qualitative study of the perspectives of small- and medium-sized enterprises. Digital Health. 2023;9:20552076231173303. doi:10.1177/20552076231173303 read 13 November 2026. doi.org/10.1177/20552076231173303

Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.

How to cite this article

Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.

Pubrica Academy. (2026, October 10). Translational Research Ecosystems: What Drives Academia-Industry Biomedical Innovation. Pubrica. https://pubrica.com/academy/concepts-definitions/a-comprehensive-assessment-of-the-literature-on-entrepreneurial-ecosystems-in-advanced-and-emerging-economies/

This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.

Translational project ecosystem checklist

Use this when planning how a biomedical discovery will move from academic research toward industry development.

[ ] Key ecosystem stakeholders identified (funders, regulators, potential industry partners)
[ ] Funding plan for the pre-commercial validation gap drafted
[ ] IP ownership and compensation terms discussed before deep collaboration begins
[ ] Bridging institution or technology-transfer pathway identified
[ ] Co-publication and collaboration plan agreed with industry partner

Pubrica AcademyWritten and maintained by the subject matter experts of Pubrica who do this work. Articles are revised when the standard underneath them moves, and each one carries the date it was last checked.

How Pubrica helps

Pubrica supports research teams preparing translational and grant-facing documentation that clearly maps the discovery against funding, regulatory and industry-partnership milestones.

Find something else

Search the rest of the Academy.

Open with no account. Type what you are working on, or open the full library to filter by category, sub-topic or resource type.

Planning how your discovery will move toward industry partnership?

A scoping read costs nothing and takes two business days. You get a written view of what the work needs and who would hold it.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.